Albemarle (NYSE:ALB) Stock Rating Lowered by Wall Street Zen

Albemarle (NYSE:ALB) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently weighed in on ALB. Morgan Stanley reaffirmed a “reduce” rating and issued a $161.00 price objective on shares of Albemarle in a report on Monday, August 10th. JPMorgan Chase & Co. lowered their target price on shares of Albemarle from $160.00 to $140.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 25th. Mizuho raised shares of Albemarle from a “neutral” rating to an “outperform” rating and set a $130.00 target price on the stock in a research note on Wednesday, October 14th. Barclays decreased their price objective on shares of Albemarle from $109.00 to $95.00 and set an “equal weight” rating for the company in a report on Friday. Finally, BMO Capital Markets restated an “outperform” rating and issued a $175.00 target price on shares of Albemarle in a research report on Tuesday, October 6th. Fifteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $177.64.

Albemarle Stock Performance

Shares of NYSE ALB opened at $99.03 on Friday. The company has a current ratio of 2.34, a quick ratio of 1.57 and a debt-to-equity ratio of 0.21. The stock has a 50 day simple moving average of $107.59 and a 200-day simple moving average of $147.87. The company has a market cap of $11.69 billion, a PE ratio of 23.92, a P/E/G ratio of 0.59 and a beta of 1.34. Albemarle has a 12-month low of $89.77 and a 12-month high of $221.00.

Albemarle (NYSE:ALB) last posted its earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Albemarle had a return on equity of 14.91% and a net margin of 10.40%. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.52 billion. During the same period last year, the firm earned ($0.19) EPS. The firm’s revenue was up 18.8% compared to the same quarter last year. On average, equities research analysts forecast that Albemarle will post 11.23 EPS for the current year.

Institutional Trading of Albemarle

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Addison Advisors LLC acquired a new stake in shares of Albemarle during the 2nd quarter valued at $28,000. Valley National Advisers Inc. grew its holdings in shares of Albemarle by 3,700.0% in the 3rd quarter. Valley National Advisers Inc. now owns 304 shares of the specialty chemicals company’s stock worth $32,000 after acquiring an additional 296 shares during the last quarter. NFSG Corp raised its position in shares of Albemarle by 470.0% during the third quarter. NFSG Corp now owns 342 shares of the specialty chemicals company’s stock worth $36,000 after purchasing an additional 282 shares during the period. Fiduciary Financial Advisors acquired a new stake in shares of Albemarle during the second quarter worth $41,000. Finally, Jones Financial Companies Lllp acquired a new position in shares of Albemarle in the 2nd quarter valued at $42,000. 92.87% of the stock is owned by institutional investors and hedge funds.

More Albemarle News

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Albemarle reported third-quarter adjusted earnings of $2.58 per share, ahead of estimates, on $1.55 billion in revenue—also above forecasts and up 18.8% year over year. Higher lithium pricing, strong demand, cost reductions and improved Specialties profits supported the results. Albemarle Q3 Earnings Call Highlights Cost Discipline and Lithium Demand
• Positive Sentiment: Scotiabank maintained its “Sector Outperform” rating and $190 price target, estimating EPS of $11.64 for FY2026 and $14.15 for FY2027—above the cited current-year consensus estimate. Albemarle analyst coverage
• Positive Sentiment: Truist reaffirmed its “buy” rating, though it lowered its price target to $170 from $185. Truist rating information
• Neutral Sentiment: RBC cut its target to $119 from $129 but retained an “outperform” rating, reflecting a more cautious valuation alongside continued optimism about the shares. RBC rating information
• Negative Sentiment: Barclays lowered its target to $95 from $109 and kept an “equal weight” rating, pointing to a less favorable near-term risk-reward view. Lithium prices remain volatile, a potential source of uncertainty for earnings. Barclays rating information

About Albemarle

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals.

The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum.

Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.